NO20014346L - Antistoff og kjemokinkonstruksjoner som er rettet mot CCR5 og deres anvendelse for å behandle autoimmune sykdommer - Google Patents

Antistoff og kjemokinkonstruksjoner som er rettet mot CCR5 og deres anvendelse for å behandle autoimmune sykdommer

Info

Publication number
NO20014346L
NO20014346L NO20014346A NO20014346A NO20014346L NO 20014346 L NO20014346 L NO 20014346L NO 20014346 A NO20014346 A NO 20014346A NO 20014346 A NO20014346 A NO 20014346A NO 20014346 L NO20014346 L NO 20014346L
Authority
NO
Norway
Prior art keywords
antibody
chemokine
autoimmune diseases
treatment
cells
Prior art date
Application number
NO20014346A
Other languages
English (en)
Other versions
NO20014346D0 (no
NO316916B1 (no
Inventor
Matthias Mack
Detlef Schloendorff
Hilke Bruehl
Original Assignee
Micromet Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micromet Ag filed Critical Micromet Ag
Publication of NO20014346D0 publication Critical patent/NO20014346D0/no
Publication of NO20014346L publication Critical patent/NO20014346L/no
Publication of NO316916B1 publication Critical patent/NO316916B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20014346A 1999-03-11 2001-09-06 Anvendelse av en bispesifikk antistoffkonstruksjon som er rettet mot CCR5 og CD3 for fremstilling av en farmasoytisk sammensetning for behandling av kronisk artritt, autoimmunesykdommer, allergiske reaksjoner eller for reduksjon av kjemokinreseptoruttrykk NO316916B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19910891 1999-03-11
PCT/EP2000/002154 WO2000053633A2 (de) 1999-03-11 2000-03-10 Antikörper- und chemokinkonstrukte, die gegen ccr5 gerichtet sind, und ihre verwendung in der behandlung von autoimmunkrankheiten

Publications (3)

Publication Number Publication Date
NO20014346D0 NO20014346D0 (no) 2001-09-06
NO20014346L true NO20014346L (no) 2001-09-27
NO316916B1 NO316916B1 (no) 2004-06-21

Family

ID=7900625

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014346A NO316916B1 (no) 1999-03-11 2001-09-06 Anvendelse av en bispesifikk antistoffkonstruksjon som er rettet mot CCR5 og CD3 for fremstilling av en farmasoytisk sammensetning for behandling av kronisk artritt, autoimmunesykdommer, allergiske reaksjoner eller for reduksjon av kjemokinreseptoruttrykk

Country Status (15)

Country Link
EP (1) EP1161456B1 (no)
JP (1) JP2002540771A (no)
CN (1) CN1345336A (no)
AT (1) ATE286074T1 (no)
AU (1) AU4104700A (no)
CA (1) CA2366713A1 (no)
CZ (1) CZ20013270A3 (no)
DE (1) DE50009113D1 (no)
ES (1) ES2233359T3 (no)
HU (1) HUP0200484A2 (no)
IL (1) IL145335A0 (no)
NO (1) NO316916B1 (no)
SK (1) SK12782001A3 (no)
TR (1) TR200102779T2 (no)
WO (1) WO2000053633A2 (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
RU2252786C2 (ru) * 2000-09-08 2005-05-27 Микромет Аг Конструкции антител и хемокинов и их применение при иммунологических нарушениях
EP1456241B1 (en) * 2001-12-21 2005-03-16 Micromet AG Mono-and dual anti-cd4-rantes chemokine/cytokine constructs
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
TW200817438A (en) 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
EP2054086A1 (en) 2006-08-17 2009-05-06 F. Hoffmann-Roche AG A conjugate of an antibody against ccr5 and an antifusogenic peptide
CN101516914A (zh) 2006-09-29 2009-08-26 霍夫曼-拉罗奇有限公司 针对ccr5的抗体及其应用
US20090143288A1 (en) 2007-03-13 2009-06-04 Roche Palo Alto Llc Peptide-complement conjugates
PT3434767T (pt) 2010-11-30 2026-01-23 Chugai Pharmaceutical Co Ltd Agente terapêutico indutor de citotoxicidade
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
AU2015244814B2 (en) 2014-04-07 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Immunoactivating antigen-binding molecule
MX2016014434A (es) 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
WO2017086367A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
WO2017086419A1 (ja) 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6428788B1 (en) * 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
ZA985542B (en) * 1997-07-03 1999-04-07 Smithkline Beecham Corp Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents
DE69910216T2 (de) * 1998-07-22 2004-02-19 Osprey Pharmaceuticals Ltd., Calgary Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung

Also Published As

Publication number Publication date
CA2366713A1 (en) 2000-09-14
WO2000053633A3 (de) 2000-11-16
CZ20013270A3 (cs) 2002-02-13
NO20014346D0 (no) 2001-09-06
WO2000053633A2 (de) 2000-09-14
ATE286074T1 (de) 2005-01-15
IL145335A0 (en) 2002-06-30
EP1161456B1 (de) 2004-12-29
NO316916B1 (no) 2004-06-21
EP1161456A2 (de) 2001-12-12
JP2002540771A (ja) 2002-12-03
ES2233359T3 (es) 2005-06-16
TR200102779T2 (tr) 2002-03-21
HUP0200484A2 (en) 2002-06-29
CN1345336A (zh) 2002-04-17
SK12782001A3 (sk) 2002-03-05
AU4104700A (en) 2000-09-28
DE50009113D1 (de) 2005-02-03

Similar Documents

Publication Publication Date Title
NO20014346D0 (no) Antistoff og kjemokinkonstruksjoner som er rettet mot CCR5 og deres anvendelse for å behandle autoimmune sykdommer
BRPI0507159A (pt) polipeptìdeos em feixe de quatro hélices humanos modificados e seus usos
EP1470146B8 (en) Antibodies against the muc18 antigen
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
NZ593428A (en) Therapeutic human anti-il-1r1 monoclonal antibody
EP1467757A4 (en) USE OF ANTIBODIES TO THE MUC18 ANTIGEN
EP2267032A3 (en) Method of administering therapeutic polypeptides, and polypeptides therefor
PL343462A1 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
DE60231868D1 (de) Folat-mimetika und deren folatrezeptorbindende konjugate
PT1641483E (pt) Proteínas de fusão
PL373567A1 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
ATE473011T1 (de) Modifizierte transferrin-fusionsproteine mit doppelten transferrin-amino- oder carboxy- terminalen domänen
DK1383785T3 (da) Rekombinant tumorspecifikt antistof og anvendelse deraf
WO2001085196A3 (en) Cxcr4 antagonist treatment of hematopoietic cells
EP2298811A3 (en) Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors
TR200000913T2 (tr) Tıbbi maddeler
BR9805012A (pt) ão de hiperuricemia em um mamìfero sofrendo de hiperuricema.
AU2001234273A1 (en) Thiazolopyrimidines and their use as modulators of chemokine receptor activity
AU5241099A (en) Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
WO2005009366A3 (en) Restoring vascular function
WO2004032850A3 (en) Uses of human zven antagonists
GB0102145D0 (en) Substances
EE05235B1 (et) Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine
ES2013321A6 (es) Un metodo de produccion de anticuerpos monoclonales
DK0839046T3 (da) TNF-receptor og steroidhormon i en kombinationsterapi